This Article Full Text Full Text (PDF) CME: Take the course for this article: Course on New Therapeutic Agents for Diabetes Mellitus Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Google Scholar Articles by Chen, D. Articles by Peterfreund, R. A. PubMed PubMed Citation Articles by Chen, D. Articles by Peterfreund, R. A. Related Collections Preoperative Evaluation Physiology Patient Safety Clinical Pharmacology Pharmacology

---

ANESTHETIC PHARMACOLOGY

New Therapeutic Agents for Diabetes Mellitus: Implications for Anesthetic Management

Daniel Chen, MD^*, Stephanie L. Lee, MD, PhD, and Robert A. Peterfreund, MD, PhD

From the *Department of Anesthesiology, Hospital for Special Surgery, New York, New York; Department of Anesthesia and Critical Care, Massachusetts General Hospital, Harvard Medical School; and Section of Endocrinology, Diabetes and Nutrition, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts.

Address correspondence to Robert A. Peterfreund, MD, PhD, Department of Anesthesia and Critical Care, Jackson 439, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114. Address e-mail to rpeterfreund{at}partners.org.

Multiple hormones and transmitter systems contribute to glucose homeostasis and the control of metabolism. Recently, the gastrointestinal peptide hormones glucagon-like peptide 1 and amylin have been shown to significantly contribute to this complex physiology. These advances provide the foundation for new treatments for diabetes mellitus. Therapies based on glucagon-like peptide 1 and amylin have now been introduced into clinical practice. Rimonabant, the selective endocannabinoid receptor antagonist, had been used in European countries for the treatment of obesity; it has recently been withdrawn for this indication. This drug exhibited therapeutic benefits for metabolic variables and for type 2 diabetes mellitus. Anesthesia providers caring for patients with diabetes mellitus will need to understand the implications of these new therapies in perioperative settings, particularly with respect to side effects and interactions.

This article has been cited by other articles:

				G. M. Hall and G. Nicholson Current Therapeutic Drugs for Type 2 Diabetes, Still Useful After 50 Years? Anesth. Analg., June 1, 2009; 108(6): 1727 - 1730. [Full Text] [PDF]